Bank of America’s Trillium Therapeutics Inc. TRIL Stock Holding History

Bank of America’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100,000	Closed	-$1.47M	–	7988
2020 Q4	$1.47M	Buy	+100,000	New	+$1.44M	﹤0.01%	4199

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Bank of America's TRIL Position: Q4 2021 in Review

Bank of America sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 286,918 shares — an estimated $5.04M sold.

Bank of America first reported a position in TRIL in Q3 2015 and held it in 20 quarters. The position peaked at $5.04M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Bank of America reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Bank of America sold 286,918 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $5.04M.
Bank of America first reported a position in Trillium Therapeutics Inc. in Q3 2015 and held it in 20 quarters.
Bank of America's Trillium Therapeutics Inc. position peaked at $5.04M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Bank of America's 13F filing for Q4 2021, filed 8 Feb 2022.